[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100444045":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":57,"centralContacts":61,"locations":66,"responsibleParty":85,"collaborators":36,"id":87,"slug":36,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":36,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":94,"maxAge":36,"enrollmentInfo":95,"targetDuration":36,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":36,"overallStatus":69,"whyStopped":36,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"ctDNA (Low Risk)","EXPERIMENTAL","Will receive less intense chemotherapy, such as capecitabine or 5-fluorouracil.",[13,14],"Drug: Leucovorin","Drug: Capecitabine",{"label":16,"type":10,"description":17,"interventionNames":18},"ctDNA (High Risk)","Will receive more intense chemotherapy. This may include resuming the chemotherapy you received before surgery (for example, FOLFOX \\[5-fluorouracil, leucovorin and oxaliplatin\\] or FOLFIRI \\[5-fluorouracil, leucovorin and irinotecan\\] with or without bevacizumab)",[13,19,20,21,14,22],"Drug: 5-FLUOROURACIL","Drug: Oxaliplatin","Drug: Irinotecan","Drug: Bevacizumab",[24,32,37,42,45,50],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Leucovorin","Given by PO",[16,9],[30,31],"Citrovorum","Wellcovorin®",{"type":25,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"5-FLUOROURACIL","Given by IV",[16],null,{"type":25,"name":38,"description":27,"armGroupLabels":39,"otherNames":40},"Oxaliplatin",[16],[41],"Eloxatin",{"type":25,"name":43,"description":34,"armGroupLabels":44,"otherNames":36},"Irinotecan",[16],{"type":25,"name":46,"description":34,"armGroupLabels":47,"otherNames":48},"Capecitabine",[16,9],[49],"Xeloda",{"type":25,"name":51,"description":34,"armGroupLabels":52,"otherNames":53},"Bevacizumab",[16],[54,55,56],"Avastin™","Anti-VEGF monoclonal antibody","rhuMAb-VEGF",[58],{"name":59,"affiliation":5,"role":60},"Timothy Newhook","PRINCIPAL_INVESTIGATOR",[62],{"name":59,"role":63,"phone":64,"phoneExt":36,"email":65},"CONTACT","(713) 794-1001","tnewhook@mdanderson.org",[67],{"facility":68,"status":69,"city":70,"state":71,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":81},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":76,"coordinates":77},"Point",[78,79],-95.36327,29.76328,{"lat":79,"lon":78},[82,84],{"name":59,"role":63,"phone":83,"phoneExt":36,"email":65},"713-794-1001",{"name":59,"role":60,"phone":36,"phoneExt":36,"email":36},{"type":86,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100444045",false,"NCT05062317","ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases","Risk-Stratified Adjuvant Therapy: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases","Inclusion Criteria:\n\n* Patients ≥18 years of age with CLM undergoing elective hepatectomy with curative intent (primary colorectal primary cancer previously removed OR being removed at time of hepatectomy) after preoperative chemotherapy (i.e., FOLFOX\u002FFOLFIRI +\u002F- bevacizumab or panitumumab\u002Fcetuximab) from 07\u002F01\u002F2021 - 12\u002F31\u002F2023\n* Must receive ≥ 4 cycles of preoperative chemotherapy\n\nExclusion Criteria:\n\n* Patients with primary colorectal tumor that will remain in situ\n* Inability to undergo postoperative chemotherapy, or postoperative chemotherapy not planned a priori\n* Unwilling\u002Funable to undergo blood draws for ctDNA, patient or provider-determined\n* Other active malignancies requiring treatment\n* Women who are pregnant","ALL","18 Years",{"count":96,"type":97},120,"ESTIMATED","INTERVENTIONAL",[100],"PHASE2","To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.",[103],"Liver Metastases","2026-02-04",{"date":106,"type":107},"2026-02-06","ACTUAL",{"date":109,"type":107},"2022-04-26",{"date":111,"type":97},"2027-02-28",{"name":5,"class":6},1]